1 / 19

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON -

Main trial design. . Double-blind. ACS (STEMI or UA/NSTEMI) and planned PCI. ASA. . PRASUGREL60 mg LD/ 10 mg MD. CLOPIDOGREL300 mg LD/ 75 mg MD. 1o end point: CV death, MI, stroke2o end point: Stent thrombosis Safety end points: TIMI major bleeds, life-threatening bleeds. Duration of ther

lela
Download Presentation

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Goals of stent analysis To compare the efficacy and safety of PRASUGREL and CLOPIDOGREL in 12,844 patients with at least one stent as part of the index procedure with respect to: Stent thrombosis (ARC definitions) Ischemic events, bleeding Overall and stratified by stent type received

    2. Main trial design

More Related